By Adedapo Adesanya
The Director General of the National Agency For Food and Drug Administration and Control (NAFDAC), Mrs Mojisola Adeyeye, has said the approval process for the R21/Matrix-M malaria vaccine requires more clinical trials before its full use.
She made this disclosure on Wednesday morning while speaking on Channels Television.
In her words, “The clinical trial will begin within the next six weeks. The RTS,S did not include Nigeria, because from the beginning the effectiveness was 30 per cent, so we did not agree to join the clinical trial.”
Mrs Adeyeye noted that development in a country’s governance is a contributing factor to the persistence of malaria in Africa.
She also stated that the provision of the vaccine is important for transmission prevention, adding that NAFDAC is going to do its own test, trials and levels of approval.
“For the R21, after reading the dossier, I believe Nigeria should join. This is because we have a high probability of success. If something is 75 per cent effective from the beginning, then we know they are very likely to be successful. It has 75 per cent effectiveness for a malaria vaccine, which is great.
Mrs Adeyeye noted that phase four clinical trials would be conducted and more laboratory work.
“However, it is not what is written only that we know as the efficacy; we have to check every line of the dossier to ensure that science speaks. This is science-driven. What we did was to have two sets of reviews,” she said.
According to her, for the first time in the agency’s history, NAFDAC is going to have an external expert body for phase four.
“We are going to do phase four clinical trials; it should be tested in our country. We are going to do more observation. This would involve more laboratory works, this cannot be administered until it goes through a testing process in the country before the transmission process,” Mrs Adeyeye disclosed.
The NAFDAC DG stated that the vaccination focus is mainly on children and not adults, adding that this was the limitation the RTS,S malaria vaccine had in its percentage efficacy.
“Even if it is only 30 per cent of the children that will not die or the death would be prevented, that will be good enough. But we didn’t take that up as an agency to be part of the trial. This particular R21 had been submitted to WHO, and they are going to be doing their own review,” she said.
“NAFDAC approved the R21 vaccine for children under five, specifically for those under three years. NAFDAC tested the second vaccine (RTSS), and it was not found effective enough. Nigeria is part of this one, that is R21; we gave provisional approval after a very rigorous approval process.”
In a related development, the world celebrated World Malaria Day yesterday (April 25) and the World Health Organisation (WHO) called on African leaders to increase their investment in health as part of efforts to rapidly reduce the burden of malaria and save the lives of its populations.
WHO Country Representative in Nigeria, Mr Walter Mulombo, made the appeal at a media roundtable to commemorate the 2023 World Malaria Day (WMD) in Abuja on Tuesday.
Mr Mulombo said malaria intervention, like any other health intervention,, should not be seen as a burden for the government or partners but as an enabling factor for social economic development.
